When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
First diagnostic centre to open in Mohali on August 31
The company has to approach the DCGI for approval to commence the trials
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Subscribe To Our Newsletter & Stay Updated
